Combination Therapy Using Chugai Pharmaceutical's Chronic Hepatitis-C Agents PEGASYS and Rivabirin Granted Priority Review Status by Government.Tokyo, Japan, Sept 14, 2005 - (JCNN JCNN Japan Corporate News Network ) - Chugai Pharmaceutical announced on September 13 that the Ministry of Health, Labor and Welfare (MHLW MHLW Ministry of Health, Labor and Welfare (Japan; formerly Ministry of Health and Welfare, MHW) MHLW Mean High Low Water (tide level) ) has granted the company with a priority review status for a combination therapy of PEGASYS (pegylated interferon alpha-2a) and rivabirin (planned trade name COPEGUS), two agents manufactured by Chugai. PEGASYS is a pegylated interferon agent that treats chronic hepatitis Chronic hepatitis Long lasting inflammation of the liver due to viruses or other causes. Mentioned in: Tube Compression of the Esophagus and Stomach chronic hepatitis C infection with a once-a-week dosage. The monotherapy using PEGASYS has been covered by the National Health Insurance since December 2003. With this move, Chugai expects to obtain approval at the earliest date as possible and contribute to the treatment of chronic hepatitis C. Results of phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for the combination therapy of PEGASYS and rivabirin were presented at the 41st Annual Conference of the Japan Society of Hepatology held in Osaka in June. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion